Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

DFG announces establishment of twelve research units

The Deutsche Forschungsgemeinschaft has established nine new Research Units and three Clinical Research Units. The decision was made by the Joint Committee of Germany's central research funding organisation at its October meeting in Bonn.

22 Oct 2011

Colon cancer may be linked to a bacterium that causes appendicitis and gum disease: Study

A new study shows that a bacterium that causes appendicitis and gum disease is also found in colon tumors. Researchers suggest that it may set the stage for colorectal cancer, the second-deadliest malignancy. The bacterium – fusobacterium might play a role in determining the prognosis of colorectal cancers and shaping their treatment, according to two research teams independently reporting a relationship between the rod-shaped microbe and cancers of the lower digestive system.

18 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

Scientists discover high levels of Fusobacterium in colorectal cancers

Scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers, a sign that it might contribute to the disease and potentially be a key to diagnosing, preventing, and treating it.

18 Oct 2011

Narrow band imaging an equally effective alternative to chromoendoscopy for dysplasia

A new study from Spain finds that narrow band imaging appears to be a less time-consuming and equally effective alternative to chromoendoscopy for the detection of dysplasia (abnormal growths) in patients with long-standing inflammatory bowel disease.

13 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

New report finds decline in clinical trial recruitment for autoimmune disorders

The number of patients recruited to clinical trials for autoimmune disorders has waned in the last ten years, according to a new report available on companiesandmarkets.com.

19 Sep 2011

AM-Pharma announces €29.2m series D round of financing

AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for treatment of severe inflammatory diseases, today announced that it has raised €29.2m in Series D financing.

13 Sep 2011

Human gliomas release excess levels of glutamate and trigger seizures

Glioma, one of the most deadly and common types of brain tumor, is often associated with seizures, but the origins of these seizures and effective treatments for them have been elusive. Now a team funded by the National Institutes of Health has found that human gliomas implanted in mice release excess levels of the brain chemical glutamate, overstimulating neurons near the tumor and triggering seizures.

12 Sep 2011

Study finds link between long-term dietary patterns and human gut bacteria

"You are what you eat" is familiar enough, but how deep do the implications go? An interdisciplinary group of investigators from the Perelman School of Medicine at the University of Pennsylvania have found an association between long-term dietary patterns and the bacteria of the human gut.

3 Sep 2011

Researchers discover expression of IL-37 that protects mice from colitis

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.

24 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.

4 Aug 2011

Researchers sample hydrogenotrophic microbes in the healthy human colon

They make up less than one-hundredth of 1 percent of the microbes that live in the colon, but the bacteria and archaea that sop up hydrogen in the gut are fundamental to colon health. In a new study, researchers take a first look at these "hydrogenotrophic" microbes, mapping where they live and how abundant they are in different parts of the lower intestine.

3 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011